RxDoctor Payments Data

Damoun Rezai

Family Medicine · Cathedral City, CANPI 1619300761

Payments from drug & device makers

$1,326in general payments, 2019–2025

Across 58 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$339
  • Lilly USA, LLC$277
  • AbbVie$182
  • Bayer$156
  • Xeris Pharmaceuticals, Inc.$64
  • Merck$48
  • plus $260 from 9 others

What the payments were for

  • Food & beverage$1,31199%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,326 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$7,480
Medicare patients
22
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$86,887
JanuviaSitagliptin Phosphate56$60,931
FarxigaDapagliflozin Propanediol50$56,660
TriumeqAbacavir/Dolutegravir/Lamivudi13$45,589
EliquisApixaban37$41,401
XareltoRivaroxaban31$34,001
KerendiaFinerenone31$31,716
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog54$27,211
JardianceEmpagliflozin20$26,769
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,332
TrulicityDulaglutide11$11,252
MounjaroTirzepatide11$11,174
Repatha SureclickEvolocumab18$10,073
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$6,938
Gabapentin172$6,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$48$60,93156 claims
PfizerEliquis$36$41,40137 claims
BayerKerendia$156$31,71631 claims
Lilly USA, LLCTrulicity, Mounjaro$277$22,42722 claims
GSKTrelegy Ellipta$39$11,33218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Cathedral City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →